MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.

OBJECTIVE This article is the first part of a two-part series on MRI safety. In this article, part 1, the topic of MRI contrast agents and nephrogenic systemic fibrosis (NSF) is addressed. CONCLUSION To prevent incidents and accidents associated with MRI, it is necessary to regularly revisit the safety topics that directly impact patient management especially with respect to the subjects that are "new" (e.g., MRI contrast agents and NSF), those that should be reassessed because of recent changes, topics that deserve emphasis because of controversy or confusion, and information that should be considered in light of new findings.

[1]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. , 2006, Seminars in arthritis and rheumatism.

[2]  Diego R. Martín,et al.  Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. , 2008, Radiology.

[3]  Nicola Vanello,et al.  Biological Effects and Safety in Magnetic Resonance Imaging: A Review , 2009, International journal of environmental research and public health.

[4]  G. Saab,et al.  Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[5]  M. Edward,et al.  Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis , 2008, The Journal of pathology.

[6]  C. Chambon,et al.  Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure , 2004, European Radiology.

[7]  G. R. Stevens,et al.  Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  W. Heindel,et al.  Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. , 2000, Investigative radiology.

[9]  A. Graham,et al.  Imaging of musculoskeletal soft tissue infections , 2010, Skeletal Radiology.

[10]  M. Ozaki,et al.  Iron release from haemosiderin and production of iron-catalysed hydroxyl radicals in vitro. , 1988, The Biochemical journal.

[11]  P. Leboit,et al.  Nephrogenic fibrosing dermopathy: two pediatric cases. , 2003, The Journal of pediatrics.

[12]  R. Bucala Circulating fibrocytes: cellular basis for NSF. , 2008, Journal of the American College of Radiology : JACR.

[13]  R. Woolson,et al.  Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  D. Broome,et al.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.

[15]  P. Anelli,et al.  Magnetic resonance contrast agents: from the bench to the patient. , 2005, Current pharmaceutical design.

[16]  Metin Akay,et al.  Wiley encyclopedia of biomedical engineering , 2006 .

[17]  L. Chibnik,et al.  Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. , 2007, Arthritis and rheumatism.

[18]  R. Reilly Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[19]  Diego R. Martín,et al.  Nephrogenic systemic fibrosis , 2007, Pediatric Radiology.

[20]  P. Colletti Nephrogenic systemic fibrosis and gadolinium: a perfect storm. , 2008, AJR. American journal of roentgenology.

[21]  H. Y. Lee,et al.  Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature , 2007, Clinical and experimental dermatology.

[22]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  R. Prayson,et al.  Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. , 2006, Archives of pathology & laboratory medicine.

[24]  F. Shellock,et al.  MRI safety update 2008: part 2, screening patients for MRI. , 2008, AJR. American journal of roentgenology.

[25]  Jacyntha A. Sterling Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy , 2007 .

[26]  V. Runge,et al.  Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.

[27]  S. Prasad,et al.  Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy: A Primer for Radiologists , 2008, Journal of computer assisted tomography.

[28]  W. Finn,et al.  Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Amy E. Chadwick,et al.  Nephrogenic Systemic Fibrosis with Multiorgan Involvement in a Teenage Male after Lymphoma, Ewing's Sarcoma, End-Stage Renal Disease, and Hemodialysis , 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[30]  S. Cowper,et al.  Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.

[31]  Charu Thakral,et al.  Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. , 2007, Contrast media & molecular imaging.

[32]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[33]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[34]  V. Runge Gadolinium and nephrogenic systemic fibrosis. , 2009, AJR. American journal of roentgenology.

[35]  R. Weenig,et al.  The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. , 2007, Seminars in cutaneous medicine and surgery.

[36]  S. Keyrouz,et al.  Neuromuscular Involvement in Nephrogenic Systemic Fibrosis , 2007, Journal of clinical neuromuscular disease.

[37]  J. Schenck Safety of Strong, Static Magnetic Fields , 2000, Journal of magnetic resonance imaging : JMRI.

[38]  P. Leboit,et al.  Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.

[39]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[40]  R. Nowack,et al.  Scleroderma-like syndrome triggered by gadolinium. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  C. Chao,et al.  Nephrogenic fibrosing dermopathy in a peritoneal dialysis patient. , 2007, Kidney international.

[42]  Frank G. Shellock,et al.  Magnetic Resonance: Bioeffects, Safety and Patient Management , 1994 .

[43]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[44]  A. Oto,et al.  Diffusion‐weighted MRI: A new tool for the diagnosis of fistula in ano , 2009, Journal of magnetic resonance imaging : JMRI.

[45]  W. Gibby,et al.  Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.

[46]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[47]  V. Runge Safety of magnetic resonance contrast media. , 2001, Topics in magnetic resonance imaging : TMRI.

[48]  R. Fennell,et al.  Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients , 2007, Pediatric Nephrology.

[49]  A. Jardine,et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. , 2007, Radiology.

[50]  K. Yoshikawa,et al.  Safety of ProHance in special populations , 1997, European Radiology.

[51]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[52]  Karen Hamilton-Persaud,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. , 2007, Nephrology nursing journal : journal of the American Nephrology Nurses' Association.

[53]  End of the road for delayed hyperenhancement cardiac magnetic resonance? , 2009, JACC. Cardiovascular imaging.

[54]  S. Swan,et al.  Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.

[55]  F. Mendoza,et al.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. , 2006, Seminars in arthritis and rheumatism.

[56]  T. Grobner Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[57]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[58]  H. Thomsen ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis , 2007, European Radiology.

[59]  G. Krestin,et al.  Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. , 1991, Investigative radiology.

[60]  Frank G Shellock,et al.  Biomedical implants and devices: Assessment of magnetic field interactions with a 3.0‐Tesla MR system , 2002, Journal of magnetic resonance imaging : JMRI.

[61]  W. Ting,et al.  Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.

[62]  Ethan M Balk,et al.  Erratum: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (Annals of Internal Medicine (2003) 139 (137-147)) , 2003 .

[63]  J. Chan,et al.  Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium , 2008, The Australasian journal of dermatology.

[64]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[65]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[66]  A. Jackson,et al.  Candidate Biomarkers of Extravascular Extracellular Space: A Direct Comparison of Apparent Diffusion Coefficient and Dynamic Contrast-Enhanced MR Imaging—Derived Measurement of the Volume of the Extravascular Extracellular Space in Glioblastoma Multiforme , 2010, American Journal of Neuroradiology.

[67]  S. Saini,et al.  Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients , 2009, Journal of magnetic resonance imaging : JMRI.

[68]  M. Jackson,et al.  Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). , 2009, Scandinavian journal of haematology.

[69]  J. Jamboti Strong association between the use of gadolinium‐based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis , 2007, Internal medicine journal.

[70]  V. Garovic,et al.  Nephrogenic Fibrosing Dermopathy , 2007 .

[71]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[72]  J. Dowling,et al.  Nephrogenic systemic fibrosis in a gadolinium‐naive renal transplant recipient , 2008, The Australasian journal of dermatology.

[73]  M. Broe Can the risk of gadolinium be extrapolated to lanthanum , 2008 .

[74]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[75]  T. Krahe,et al.  Pharmakokinetik von Gadolinium-DTPA bei dialysepflichtiger chronischer Niereninsuffizienz , 1992 .

[76]  P. Hauschka,et al.  Incorporation of excess gadolinium into human bone from medical contrast agents. , 2009, Metallomics : integrated biometal science.

[77]  F. Shellock,et al.  MR procedures: biologic effects, safety, and patient care. , 2004, Radiology.

[78]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[79]  R. Semelka,et al.  Nephrogenic systemic fibrosis and management of high-risk patients. , 2009, Academic radiology.

[80]  N. Scheinfeld Nephrogenic Fibrosing Dermopathy , 2006, American journal of clinical dermatology.

[81]  H. Pieringer,et al.  Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[82]  S. Cowper,et al.  Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients , 2006, Seminars in dialysis.

[83]  F G Shellock,et al.  Auditory noise associated with MR procedures: a review. , 2000, Journal of magnetic resonance imaging : JMRI.

[84]  J D Bourland,et al.  Review of Patient Safety in Time‐Varying Gradient Fields , 2000, Journal of magnetic resonance imaging : JMRI.

[85]  D. Fiorentino,et al.  Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. , 2007, Archives of dermatology.

[86]  G. Scott,et al.  Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. , 2007, Journal of the American Academy of Dermatology.

[87]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.

[88]  J. Topf,et al.  Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.

[89]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[90]  J. Goulle,et al.  Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. , 2008, Forensic science international.

[91]  H. Thomsen Nephrogenic Systemic Fibrosis , 2008 .

[92]  E. Kanal,et al.  Gadolinium‐induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury , 2007, The British journal of dermatology.

[93]  L. Robinson-Bostom,et al.  Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. , 2008, Journal of the American Academy of Dermatology.

[94]  P. Gerke,et al.  Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent. , 2007, Clinical nephrology.

[95]  S. Textor,et al.  Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. , 2007, Nephrology, Dialysis and Transplantation.

[96]  D. Tudorascu,et al.  Nephrogenic systemic fibrosis: Center case review , 2007, Journal of magnetic resonance imaging : JMRI.

[97]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[98]  S. Cowper,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment , 2008, Seminars in dialysis.

[99]  F. Shellock,et al.  Policies, guidelines, and recommendations for MR imaging safety and patient management , 1991, Journal of magnetic resonance imaging : JMRI.

[100]  G. Choppin,et al.  Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. , 2001, Inorganic chemistry.

[101]  H. Hussain,et al.  Nephrogenic systemic fibrosis: a report of 29 cases. , 2008, AJR. American journal of roentgenology.

[102]  Henrik S. Thomsen,et al.  Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[103]  E. Poch,et al.  Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor , 2007, The British journal of dermatology.

[104]  S. Cowper Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.

[105]  J. S. Mann,et al.  Stability of Gadolinium Complexes In Vitro and In Vivo , 1993, Journal of computer assisted tomography.

[106]  B. Warady,et al.  Nephrogenic fibrosing dermopathy in children , 2006, Pediatric Nephrology.

[107]  Emanuel Kanal,et al.  Guidelines and recommendations for MR imaging safety and patient management III. Questionnaire for screening patients before MR procedures , 1994, Journal of magnetic resonance imaging : JMRI.

[108]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[109]  C. Schmid,et al.  Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[110]  Tom Greene,et al.  Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)) , 2008 .

[111]  F. Cosio,et al.  Growing Pains from The Islet Cell Transplant World , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[112]  R. Bucala,et al.  Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) , 2006, Current opinion in rheumatology.

[113]  S. Quérin,et al.  La fibrose systémique néphrogénique : nouveau coup dur pour les insuffisants rénaux , 2007 .

[114]  M. Tweedle "Stability" of gadolinium chelates. , 2007, The British journal of radiology.

[115]  L. Skov,et al.  Nephrogenic systemic fibrosis: A serious iatrogenic disease of renal failure patients , 2007, Scandinavian journal of urology and nephrology.

[116]  Tom Greene,et al.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.

[117]  J. Kay What Causes Nephrogenic Systemic Fibrosis , 2008 .

[118]  E. Simpson,et al.  Gadolinium Is Not the Only Trigger for Nephrogenic Systemic Fibrosis: Insights From Two Cases and Review of the Recent Literature , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[119]  M. Kirchin,et al.  Nephrogenic systemic fibrosis: The need for accurate case reporting , 2009, Journal of Magnetic Resonance Imaging.

[120]  N. Powe,et al.  Principles of screening for chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[121]  P. Cheung,et al.  Nephrogenic fibrosing dermopathy: a new clinical entity mimicking scleroderma , 2007, Internal medicine journal.

[122]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[123]  V. Werth,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature , 2007, International journal of dermatology.

[124]  Frank G. Shellock,et al.  Reference Manual for Magnetic Resonance Safety, Implants, and Devices , 2009 .

[125]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[126]  T. Grobner,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Patient Characteristics and Risk Factors for Nephrogenic Systemic Fibrosis Following Gadolinium Exposure , 2008, Seminars in dialysis.

[127]  P. Kuo Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. , 2008, Journal of the American College of Radiology : JACR.

[128]  F G Shellock,et al.  Radiofrequency Energy‐Induced Heating During MR Procedures: A Review , 2000, Journal of magnetic resonance imaging : JMRI.

[129]  G. Schwartz,et al.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine , 2004 .